Not only does this show Pfizer has huge cash reserves and the ability to pay a fair price for RAP. The offer is a 78% premium on Biohaven's closing share price, while the RAP offer is only a 27.8% premium on the share price. Vote NO!
- Forums
- ASX - By Stock
- RAP
- Valuing ResApp Health
Valuing ResApp Health, page-40
-
- There are more pages in this discussion • 427 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online